What drove the intraday drop in BIT.AX stock today?

BIT.AX stock fell **14.29%** intraday mostly due to low liquidity and investor reaction to biotech risk factors. Key drivers are trial uncertainty for BIT225, micro-cap volatility and the small market cap of **A$4,981,740.00** which amplifies selling pressure.

What is Meyka AI’s view and grade on BIT.AX stock?

Meyka AI rates BIT.AX **60.77/100**, Grade **B**, Suggestion: **HOLD**. The grade reflects sector comparison, growth metrics, key financials and limited analyst coverage. This is informational and not investment advice.

What are realistic price targets for BIT.AX stock?

Scenario targets: base **A$0.004** (implied **+33.33%**), bear **A$0.002** (implied **-33.33%**), bull **A$0.006** (implied **+100.00%**). Targets factor in trial outcomes, dilution risk and thin liquidity. Forecasts are not guarantees.

How should investors monitor BIT.AX stock moving forward?

Watch Biotron’s earnings on **26 Feb 2026**, clinical updates for BIT225, cash and funding announcements, and ASX liquidity. Use stop sizing for micro-cap swings and consult Meyka AI’s live data for real-time signals.

AU Stocks

BIT.AX Biotron Limited ASX down 14.29% intraday 05 Feb 2026: Key risk ahead

ByDanny Kontos February 5, 2026February 5, 2026

BIT.AX stock slid 14.29% intraday on 05 Feb 2026, trading at A$0.003 after opening at A$0.003. Volume is elevated at 5,655,705 shares versus an average of 4,504,495, underlining active selling. Biotron Limited (BIT.AX) on the ASX remains a micro-cap biotech with a market cap of A$4,981,740.00 and ongoing clinical and cash-flow risks that are driving the move. We examine valuation, key metrics and short-term catalysts for traders and holders.